HGEN Humanigen Inc

Humanigen, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of cell and gene therapies for the treatment of cancers through novel human granulocyte-macrophage colony-stimulating factor neutralization and gene-knockout platforms. The company was founded by Jeng-Horng Her & Robert F. Balint on March 15, 2000 and is headquartered in Burlingame, CA.

$0.17  +0.02 (12.41%)
As of 09/23/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/31/2013
Outstanding shares:  103,660,938
Average volume:  3,972,861
Market cap:   $17,933,342
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BM9GXF8
Valuation   (See tab for details)
PE ratio:   -0.09
PB ratio:   0.55
PS ratio:   4.33
Return on equity:   767.93%
Net income %:   -4,640.77%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy